Indications

Atezolizumab is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (UC):

After prior chemotherapy, or

Who are considered cisplatin ineligibleand whose tumours have a PD-L1 expression ≥ 5%, or

Who are not eligible for any platinum-containing chemotherapy regardless of level of tumor PD-L1 expression.

Atezolizumab is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer NSCLC after prior chemotherapy.

Dosage & Administration

General: Atezolizumab must be administered as an intravenousinfusion under the supervision of a qualified healthcare professional. Do not administer as an IV push or bolus. Substitution by any other biological medicinal product requires the consent of the prescribing physician. The initial dose of Atezolizumab must be administered over 60 minutes. If the first infusion is tolerated all subsequent infusions may be administered over 30 minutes. The recommended dose of Atezolizumab is either:

1200 mg administered by IV infusion every 3 weeks or

1680 mg administered by IV infusion every 4 weeks.

1L cisplatin-ineligible mUC: Patients should be selected for treatment based on the tumor expression of PD-L1 confirmed by a validated test

* চিকিৎসকের পরামর্শ মোতাবেক নিয়মিত ঔষধ সেবন করুন